For a medicine question in pregnancy, use UKTIS for specialist evidence interpretation, BUMPS for information the patient can revisit, and the Summary of Product Characteristics for the specific product's authorised information. They answer related questions, not interchangeable ones. A cautious product label and a more reassuring specialist assessment are not necessarily contradictory.
This guide compares their documented roles as checked on 6 September 2026. It is published by iatroX, which is included below as a clinical reference and learning resource, not as a replacement for specialist teratology advice.
First decide what the patient is asking
"Can I take this in pregnancy?" might mean several things. Someone may have taken a medicine before discovering the pregnancy, be considering starting treatment, or be deciding whether to continue a treatment that has kept a serious condition controlled. These situations require different comparisons.
For an inadvertent exposure, establish what was actually taken and when. For a proposed treatment, establish the indication and realistic alternatives. For ongoing treatment, include the consequences of stopping or changing it. Record gestation, the timing and duration of exposure, relevant illness, other medicines and the patient's principal concern. A search cannot repair a question that omits the decision being made.
Write the clinical question before opening a browser. For example: "A patient with recurrent depression, currently well on treatment, has discovered an early pregnancy. What evidence should inform continuation, and what counselling or specialist input is needed?" That is more useful than asking a website to classify a medicine as simply safe or unsafe.
The three resources have different jobs
| Resource | Most useful contribution | What it does not establish alone |
|---|---|---|
| UKTIS | Professional assessment of evidence about exposure during pregnancy | The complete plan for an individual patient |
| BUMPS | Accessible explanations for patients and families | A substitute for assessment of a complex exposure |
| SmPC | Product-specific authorised information, including pregnancy and lactation wording | A complete synthesis of every subsequent observational study |
UKTIS describes its professional teratology information service and its relationship with BUMPS, the patient-facing medicines-in-pregnancy resource. As checked on 6 September 2026, public UKTIS summaries are available, while access arrangements for fuller professional material differ. Do not assume a patient leaflet is the entirety of the professional evidence review.
The NHS Specialist Pharmacy Service resource guide, updated 15 July 2025, explains why product information may be cautious when pregnancy data are limited. SmPC section 4.6 is relevant, but its wording should be interpreted alongside specialist pregnancy information. The absence of reassuring licence wording is not, by itself, evidence that an exposure has caused harm.
A synthetic case: an early pregnancy and an established antidepressant
Consider a fictional patient taking sertraline for recurrent depression. She is seven weeks pregnant, feels well and has read a warning in the medicine leaflet. During an earlier episode she stopped treatment without advice and became substantially unwell. She now asks whether she should stop immediately.
The first response is not to read a risk label aloud. Clarify her current mental health, previous illness, the exposure and any immediate safety concerns. Explain that the decision involves both treatment-related uncertainty and the risk associated with losing control of the condition. This is an assessment framework, not an instruction to continue or discontinue a particular prescription.
The UKTIS sertraline monograph, checked on 6 September 2026, describes conflicting findings, with most studies not demonstrating a statistically significant increase in overall or cardiovascular malformations after first-trimester exposure. That wording does not mean zero risk. It also does not support telling this patient that a warning in a leaflet proves her baby has been harmed.
Now inspect the exact product information, rather than a different formulation returned by a search. Identify what the pregnancy section says, its update date and whether any advice relates to later exposure rather than the exposure under discussion. Then use the relevant BUMPS information to support the explanation, after checking that it addresses the same medicine and situation.
Explain the uncertainty without transferring the decision to the patient
A useful explanation might begin: "The product information is cautious, and the specialist pregnancy resource considers a wider body of evidence. Neither gives a guarantee. We also need to consider what happened when your illness was untreated and agree a plan with the appropriate clinical team."
That wording is an original counselling example, not a quotation from UKTIS. Its purpose is to make the reasoning visible. Avoid a recital of every adverse outcome mentioned anywhere in the literature. Establish which outcomes are relevant to this exposure, how strong the evidence is, and what information would alter the plan.
Before ending, ask what the patient understood. "What will you do about the medicine after we finish today?" can uncover a dangerous misunderstanding that "Any questions?" misses. Agree who will obtain further advice, how the patient will receive it and what to do if her mental health deteriorates in the meantime.
Leave a record another clinician can follow
A defensible entry identifies the medicine and indication, pregnancy timing, the sources and dates consulted, the main uncertainty, the patient's priorities and the agreed action. Record the reason for seeking specialist advice, not merely "discussed risks". Distinguish advice already received from advice requested and still outstanding.
In the fictional case, a useful learning note would identify the specific tension: limited pregnancy evidence versus a documented history of relapse after treatment interruption. It would not state that a website certified the medicine as safe.
Which resource should you use next?
For a complex exposure or unresolved risk assessment, UKTIS and the relevant specialist team are the appropriate next step. For an explanation the patient can revisit, BUMPS is the better fit. For authorised product details, return to the exact SmPC.
For a broader clinical question or a learning gap, Ask-iatroX provides free linked-source clinical reference, as described in September 2026. Its published retrieval and citation methodology describes how answers are constructed, not a guarantee of correctness or access to every specialist monograph. A useful follow-on learning task is to explain why changing a stable treatment and assessing an inadvertent exposure are different questions.
Frequently asked questions
Is BUMPS the same as UKTIS?
BUMPS is the patient-facing medicines-in-pregnancy resource associated with UKTIS. Its accessible explanations complement, rather than replace, professional assessment of a complex case.
Does cautious SmPC wording mean a medicine must always be stopped?
No, the wording must be interpreted with the indication, exposure and specialist evidence. A treatment change needs an individual clinical decision, not an isolated sentence from a search result.
Can an AI answer replace specialist pregnancy advice?
No, it can help organise a question and locate linked information, but unresolved or complex pregnancy medicines decisions require the appropriate specialist input. Verify the underlying sources before relying on a summary.